OncoZenge AB (OSTO:ONCOZ) Change In Inventory : kr0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is OncoZenge AB Change In Inventory?

OncoZenge AB's change in inventory for the quarter that ended in Dec. 2024 was kr0.00 Mil. It means OncoZenge AB's inventory stayed the same from Sep. 2024 to Dec. 2024 .

OncoZenge AB's change in inventory for the fiscal year that ended in Dec. 2024 was kr0.00 Mil. It means OncoZenge AB's inventory stayed the same from Dec. 2023 to Dec. 2024 .

OncoZenge AB's Total Inventories for the quarter that ended in Dec. 2024 was kr0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

OncoZenge AB Change In Inventory Historical Data

The historical data trend for OncoZenge AB's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoZenge AB Change In Inventory Chart

OncoZenge AB Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Inventory

OncoZenge AB Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Inventory	Get a 7-Day Free Trial												-	-	-	-	-

OncoZenge AB Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

OncoZenge AB (OSTO:ONCOZ) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

OncoZenge AB's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

OncoZenge AB's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

OncoZenge AB's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

OncoZenge AB Change In Inventory Related Terms

Thank you for viewing the detailed overview of OncoZenge AB's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoZenge AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (OSTO:ONCOZ) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

8LY:Germany

Address

Gustavslundsvagen 34, Bromma, SWE, 167 51

Website

https://www.oncozenge.com

OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

OncoZenge AB Headlines

No Headlines